“In 2025, we will once again deliver strong share gain, and our PPI Business System will enable outstanding execution and we will deliver very strong earnings growth.”

In context

“d's most innovative companies by Fast Company for our significant contributions in diagnostics that help to advance health equity. Additionally, we continue to advance our STEM education programs, reaching more than 180,000 students globally. This helps to ensure we have students engaged in the sciences as, ultimately, they'll become our future customers. As I reflect on the year, I'm very proud of what our team accomplished. We have more than 120,000 passionate colleagues who are dedicated to enabling our customer success and advancing science. Together, we continue to build a bright future for our company, and I'm very excited about the year ahead. So let me now turn to guidance. Stephen will outline the assumptions that factor into the guidance, but let me quickly cover the highlights. In 2025, we will once again deliver strong share gain, and our PPI Business System will enable outstanding execution and we will deliver very strong earnings growth. We're initiating a 2025 revenue guidance in the range of $43.5 billion to $44 billion, which assumes 3% to 4% organic growth. And an adjusted EPS guidance range of $23.10 to $23.50, which represents 6% to 8% growth in adjusted earnings per share. We're in a great position as we enter 2025. I'm incredibly excited by the opportunities we have with our customers and to create value for all of our stakeholders and build an even brighter future for our company. So to summarize our key takeaways for 2024. Our proven growth strategy continued to drive significant share gain. We continued to elevate our trusted partner status and deepen the relationships with many customers. And this, in combination with the power of our PPI Business System, enabled us to deliver an excellent finish to 2024 with”